Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ALT-803 + Cyclophosphamide + PD-L1.t-haNK cells + Sacituzumab govitecan-hziy|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ALT-803||N-803|N803|N 803|nogapendekin alfa|ALT803|ALT 803||ALT-803 (nogapendekin alfa) is a fusion protein comprising a mutant version of IL-15 with increased activity and IL-15Ra fused to the Fc region of IgG1, which activates CD8+ T-cells and promotes effector activity, potentially resulting in increased antitumor immune response (PMID: 24404427, PMID: 31338557).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|PD-L1.t-haNK cells||PD-L1 t-haNK|Allogeneic PD-L1-t-haNK||PD-L1.t-haNK cells are natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) that targets PD-L1, which may induce cell killing in PD-L1-expressing tumor cells resulting in decreased tumor growth (PMID: 32439799).|
|Sacituzumab govitecan-hziy||Trodelvy||IMMU-132|Sactizumab|Sacituzumab govitecan||TROP2 Antibody 7||Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2 positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586). Trodelvy (sacituzumab govitecan-hziy) is FDA approved for use in patients with metastatic triple-negative breast cancer who received two or more prior therapies, in patients with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies, and in patients with locally advanced or metastatic urothelial cancer who received a platinum-containing chemotherapy and a PD-1 orPD-L1 inhibitor (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04927884||Phase Ib/II||ALT-803 + Cyclophosphamide + PD-L1.t-haNK cells + Sacituzumab govitecan-hziy||A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies||Terminated||USA||0|